India’s immunisation plan against Covid-19 may get bolstered soon with the rollout of locally manufactured single-dose Sputnik Light in September. Panacea Biotec, which had earlier partnered Russian Direct Investment Fund (RDIF), has submitted the dossier for seeking emergency-use authorisation to India’s drug regulator recently, sources told TOI. The vaccine, which will be available in limited quantities initially, is expected to be priced around Rs 750.India’s immunisation plan against Covid-19 may get bolstered soon with the rollout of locally manufactured single-dose Sputnik Light in September. Panacea Biotec, which had earlier partnered Russian Direct Investment Fund (RDIF), has submitted the dossier for seeking emergency-use authorisation to India’s drug regulator recently, sources told TOI. The vaccine, which will be available in limited quantities initially, is expected to be priced around Rs 750.